Skip to main content
. 2024 Apr 23;30(5):1330–1338. doi: 10.1038/s41591-024-02942-7

Extended Data Fig. 2. Full mutation Oncoprint for the entire patient cohort.

Extended Data Fig. 2

Extended Data Fig. 2 Full mutation Oncoprint for the entire patient cohort. Patients are separated on the basis of clinical benefit, defined by progression-free survival (PFS) ≥24 weeks (n = 19) and PFS < 24 weeks (n = 14).